PEG-P-INF alfa-2b: Phase I/II data

Data from 11 evaluable patients in the Phase II portion of the open-label, Austrian Phase I/II PEGINVERA trial showed that subcutaneous AOP2014 given every 2 weeks produced an ORR of 91% at 12 months, including 5 complete response and 5 partial responses. Safety data from 41 patients showed that AOP2014 was well tolerated with no dose-limiting toxicities (DLTs) observed in the 50-540 µg dose range. Data were presented at the American Society of Hematology meeting in Atlanta. ...